Drug updated on 5/17/2024
Dosage Form | Injection (intravenous; 5 g/50 mL, 10 g/100 mL) |
Drug Class | Fatty acids |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC).
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Fish oil triglycerides (Omegaven) are indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC). Omegaven has shown significant clinical advantages over other types of intravenous lipid emulsions (ILEs) in adult hospitalized patients, including reduced risks of infection and sepsis, and decreased hospital length of stay.
- Four studies provided comprehensive assessments of the effectiveness and safety of Omegaven compared to other ILEs or interventions.
- One study discussed the impact of omega-3 fatty acids supplementation on serum levels of brain-derived neurotrophic factor (BDNF). This suggests potential implications for neurological health and cognitive functions due to increased BDNF levels from omega-3 FAs found in Omegaven.
- Another study focused on nutritional interventions for children under 5 years old in Ethiopia mentioned the potential benefits of fish oil supplementation, indicating possible roles for Omegaven within nutritional support contexts aimed at alleviating malnutrition consequences like wasting.
- A review addressing the safety and efficacy of different lipid emulsions showed a significant reduction in cholestasis with fish oil LE like Omegaven compared to soybean-oil based LE among infants with gastrointestinal failure or PNALD. It also reported better weight gain but higher gamma-glutamyl transferase levels when using MOFS-based LE versus S-based ones; however, it concluded that there was insufficient data to prioritize any one type due to limitations such as small study sizes or early trial terminations.
- The comparison between population/subgroup considerations shows superior safety/effectiveness against infections/sepsis/hospital stays duration among adults receiving parenteral nutrition, while promising results in reducing childhood wasting/improving nutritional status need further integrated approaches as advised by nutritional intervention studies.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Omegaven (fish oil triglycerides) Prescribing Information. | 2020 | Fresenius Kabi USA LLC, Grand Island, NY |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Omega-3 fatty acids in parenteral nutrition – a systematic review with network meta-analysis on clinical outcomes. | 2023 | Clinical Nutrition |
A systematic review and meta-analysis of the omega-3 fatty acids effects on brain-derived neurotrophic factor (BDNF). | 2023 | Nutritional Neuroscience |
Interventions to improve the nutritional status of under five children in Ethiopia: a systematic review. | 2023 | Public health Nutrition |
Lipid emulsions for parenterally fed term and late preterm infants. | 2019 | The Cochrane Database of Systematic Reviews |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Complications in and treatment of pediatric patients receiving long-term parenteral nutrition. | 2022 | Advances in Pediatric Surgery |
ESPEN practical guideline: clinical nutrition in liver disease. | 2020 | Clinical Nutrition |